ClinicalTrials.gg
CompletedNCT00635349Updated Jul 22, 2013Results posted

A Comparative Study of Tramadol Hydrochloride Plus Acetaminophen Tablets Maintenance Versus Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Maintenance in Participants With Knee Osteoarthritis

A Phase 4 interventional study of Meloxicam and Aceclofenac in Osteoarthritis, sponsored by Janssen Korea, Ltd., Korea. Completed. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-07-22.

Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing acetaminophen in Osteoarthritis — none open to participants now, none under way, none of them phase 3. Acetaminophen · Osteoarthritis.

Enrollment
5th of 14
143 · median 79
Started
2007
with 1 other
Phase 4
7 of 14
none open now
Registered
5th of 14
by date
Lead sponsor
1 of 14
Janssen Korea, Ltd., Korea

Among the 14 studies testing acetaminophen in Osteoarthritis, this one is the 5th largest by enrollment, is one of 2 that started in 2007, is one of 7 in phase 4, and was the 5th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 14 studies testing acetaminophen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing acetaminophen in Osteoarthritis as a file.
02

Study summary

The purpose of this study is to compare the effectiveness of tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg maintenance with that of non-steroidal anti-inflammatory drugs (NSAIDs) maintenance in participants with knee osteoarthritis (a progressive and degenerative joint disease, in which the joints become painful and stiff) whose pain was relieved after the add-on treatment of tramadol hydrochloride to NSAIDs.

Read the detailed description

This is a multicenter (when more than one hospital or medical school team work on a medical research study), randomized (the study drug is assigned by chance), open-label (all people know the identity of the intervention), comparative study to compare the efficacy of tramadol hydrochloride plus acetaminophen maintenance with that of NSAIDs maintenance in participants whose pain was relieved after the add-on treatment of tramadol 37.5 milligram (mg) plus acetaminophen 325 mg to NSAIDs. All participants will receive tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam [7.5 mg or 15 mg once daily] or aceclofenac [100 mg twice daily]) from Day 1 to Day 28, and participants will be randomly assigned into 2 treatment groups at Day 29 if the numerical rating scale score less than or equal 4. Tramadol plus acetaminophen group will receive 1 or 2 tablets containing tramadol 37.5 mg plus acetaminophen 325 mg 4 times daily (maximum daily dose will be 8 tablets) from Day 29 to Day 85 and NSAIDs group will receive either meloxicam 7.5 mg or 15 mg per day or aceclofenac 100 mg twice a day from Day 29 to Day 85. The efficacy will be evaluated on Day 1, Day 29, Day 57 and Day 85. The primary efficacy end point will be assessed through change in Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) total score from Day 29 to Day 85. Participant's safety will be monitored throughout the study.

03

Conditions studied

  • Osteoarthritis

Keywords

  • WOMAC
  • Knee osteoarthritis pain
  • Pain intensity
  • Tramadol
  • Acetaminophen
  • Meloxicam
  • Aceclofenac
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have suffered from knee osteoarthritis at least for one year and meet the criteria of American College of Rheumatology
  • Participants who are taking stable dose of meloxicam 7.5 milligram (mg) or 15 mg daily or aceclofenac 100 mg twice a day at least for four weeks
  • Participants whose mean pain intensity has been 5 or higher on the numeric rating scale (NRS) for the last 48 hours
  • Participants whose general health conditions are favorable, according to the criteria below: Medical and medication history, Physical examination before the study medication administration, Vital signs: Blood pressure, pulse, Clinical laboratory tests: Serum glutamic oxaloacetic transaminase ()/serum glutamic pyruvate transaminase (SGPT) less-than or equal to (=\<) 2 X normal range, Renal function: Creatinine less than (\<) 2.0 milligrams per deciliter (mg/dl)
  • Female participants of to use the proper methods during the study period (Urine pregnancy test prior to the study participation should be negative)

Exclusion criteria

Exclusion Criteria:

  • Participants who are applicable to Kellgren and Lawrence grade
  • Participants who had failed tramadol treatment before or stopped taking tramadol due to adverse event(s)
  • Participants who are applicable to one of the following conditions: Rheumatoid arthritis, Ankylosing spondylitis, Active gout or active pseudo-gout, Diagnosis of fibromyalgia (according to ACR Criteria), Anserine bursitis, Major trauma of the target joint within six months prior to the study medication administration, Infection of the target joint within six months prior to the study medication administration, Apparent avascular necrosis of the target joint within six months prior to the study medication administration, Anatomical deformities of the target joint, which may interfere with assessment of the target joint, Surgical procedures associated with the target joint within one year prior to the study medication administration, Arthroscopic procedures associated with the target joint within six months prior to the study medication administration
  • Participants who have one of the following diseases: Significantly unstable diseases such as sleep disorder (e.g., sleep apnea or narcolepsy) or dementia, Functional damage or disease which may cause malabsorption, excessive accumulation, or metabolism or excretion disorder
  • Participants who are pregnant or breast-feeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Active comparator
    Non-steroidal Anti-inflammatory Drug (NSAIDs)

    Participants will receive fixed dose combination of tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numeric rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of NSAIDs to receive either meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 29 to Day 85.

    Drug: Meloxicam · Drug: Aceclofenac · Drug: Tramadol Hydrochloride Plus Acetaminophen

  • Experimental
    Tramadol Hydrochloride Plus Acetaminophen

    Participants will receive fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numerical rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).

    Drug: Meloxicam · Drug: Aceclofenac · Drug: Tramadol Hydrochloride Plus Acetaminophen

Interventions

  • Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.

  • Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.

  • DrugTramadol Hydrochloride Plus Acetaminophen

    Drug pages: Tramadol · Acetaminophen

    Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).

06

What researchers measure

Primary outcomes

  1. Change From Day 29 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total Score at Day 85

    The WOMAC is a self-administered and health status questionnaire designed to capture elements of pain, stiffness and physical impairment in participants with osteoarthritis. It consists of 24 questions (5 questions about pain, 2 about stiffness and 17 about physical function) scored on a visual analog scale (VAS) of 0 to 10 cm (0 cm=no pain to 10 cm=worse pain). Individual question responses are assigned a score between 0=extreme and 4=none. Maximum scores for each element differ and therefore, scores were normalized. Total normalized score ranges from 0=worst to 100=best.

    Time frame: Day 29 and Day 85

Secondary outcomes

  1. Change From Day 29 in Pain Intensity Score at Day 85

    Pain intensity was evaluated by 11- point numeric rating scale ranging from 0 to 10 where, 0=no pain and 10=pain as bad as you can imagine.

    Time frame: Day 29 and Day 85

  2. Number of Participants With Pain Relief

    Pain relief was assessed by using a 6-point scale ranging from -1 to 4 where, -1=pain aggravated, 0=no change, 1=slightly relieved, 2=moderately relieved, 3=considerably relieved, and 4=pain completely disappeared. Participants with pain slightly relieved, moderately relieved and completely disappeared were considered as pain relieved.

    Time frame: Day 29, Day 57 and Day 85

  3. Number of Participants With Overall Assessment on Study Drug by Participants

    Participants' overall assessment on study drug was done by using a 5-point scale ranging from -2 to 2 where, -2= very bad, 1= bad, 0=moderate, 1=good and 2=very good. Study drug refers specifically to the randomized treatment received from Day 29 to Day 85.

    Time frame: Day 85

  4. Number of Participants With Overall Assessment on Study Drug by Investigator

    Investigator was completed overall assessment on study drug by using a 5-point scale (-2 to 2; where, -2= very bad, 1= bad, 0=moderate, 1=good and 2=very good). Study drug refers specifically to the randomized treatment received from Day 29 to Day 85.

    Time frame: Day 85

  5. Number of Participants With Categorical Swelling

    Swelling was assessed by using a 4-point scale ranging from 0 to 3 where, 0=no swelling, 1=presence of cross fluctuation of fluid (PCFF), 2=patellar ballotment, and 3=swelling that distort the joint contours (SDJC).

    Time frame: Day 29, Day 57 and Day 85

  6. Number of Participants With Categorical Tenderness

    Tenderness was assessed by using a 4-point scale 0 to 3 where, 0= no tenderness, 1= complaint of tenderness, 2=complaint of tenderness with wincing (CTW), and 3=wincing and attempt to withdraw.

    Time frame: Day 29, Day 57 and Day 85

07

Results

Posted Jun 24, 2013
Limitations and caveats
There was no wash-out period after Day 28 to show drug efficacy in participants whose pain was already relieved and results were not meet the objective by setting inappropriate non-inferiority limit by applying WOMAC total score in hypothesis.

Participant flow

Participant flow — Overall Study
MilestoneNon-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus Acetaminophen
Started7367
Completed2919
Not completed4448
Withdrew: Other86
Withdrew: Protocol violation1822
Withdrew: Withdrawal by subject38
Withdrew: Lost to follow-up43
Withdrew: Adverse event119

Outcome measures

PrimaryChange From Day 29 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total Score at Day 85

The WOMAC is a self-administered and health status questionnaire designed to capture elements of pain, stiffness and physical impairment in participants with osteoarthritis. It consists of 24 questions (5 questions about pain, 2 about stiffness and 17 about physical function) scored on a visual analog scale (VAS) of 0 to 10 cm (0 cm=no pain to 10 cm=worse pain). Individual question responses are assigned a score between 0=extreme and 4=none. Maximum scores for each element differ and therefore, scores were normalized. Total normalized score ranges from 0=worst to 100=best.

Time frame:
Day 29 and Day 85
Reported as:
Mean · units on a scale
Change From Day 29 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total Score at Day 85
units on a scaleNon-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus Acetaminophen
Day 2933.54 ± 15.0139.44 ± 14.17
Change at Day 85-1.88 ± 11.07-0.07 ± 13.46
Statistical analysis
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs) vs Tramadol Hydrochloride Plus Acetaminophen · t-test, 1 sided · p = 0.4258 · Mean difference (final values): 1.81
SecondaryChange From Day 29 in Pain Intensity Score at Day 85

Pain intensity was evaluated by 11- point numeric rating scale ranging from 0 to 10 where, 0=no pain and 10=pain as bad as you can imagine.

Time frame:
Day 29 and Day 85
Reported as:
Mean · units on a scale
Change From Day 29 in Pain Intensity Score at Day 85
units on a scaleNon-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus Acetaminophen
Day 293.82 ± 1.223.81 ± 1.03
Change at Day 850.14 ± 1.760.83 ± 2.02
Statistical analysis
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs) vs Tramadol Hydrochloride Plus Acetaminophen · t-test, 1 sided · p = 0.0628 · Mean difference (final values): -0.68
SecondaryNumber of Participants With Pain Relief

Pain relief was assessed by using a 6-point scale ranging from -1 to 4 where, -1=pain aggravated, 0=no change, 1=slightly relieved, 2=moderately relieved, 3=considerably relieved, and 4=pain completely disappeared. Participants with pain slightly relieved, moderately relieved and completely disappeared were considered as pain relieved.

Time frame:
Day 29, Day 57 and Day 85
Reported as:
Number · participants
Number of Participants With Pain Relief
participantsNon-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus Acetaminophen
Day 29; Pain relieved (n=56, 52)4942
Day 57; Pain relieved (n=47, 41)3228
Day 85; Pain relieved (n=55, 56)4235
Statistical analysis
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs) vs Tramadol Hydrochloride Plus Acetaminophen · Fisher Exact · p = 0.0131 (Day 29: p-value was calculated by fisher exact test)
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs) vs Tramadol Hydrochloride Plus Acetaminophen · Chi-squared · p = 0.9834 (Day 57; p-value was calculated by Chi-squared test)
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs) vs Tramadol Hydrochloride Plus Acetaminophen · Chi-squared · p = 0.1131 (Day 85; p-value was calculated by Chi-squared test)
SecondaryNumber of Participants With Overall Assessment on Study Drug by Participants

Participants' overall assessment on study drug was done by using a 5-point scale ranging from -2 to 2 where, -2= very bad, 1= bad, 0=moderate, 1=good and 2=very good. Study drug refers specifically to the randomized treatment received from Day 29 to Day 85.

Time frame:
Day 85
Reported as:
Number · participants
Number of Participants With Overall Assessment on Study Drug by Participants
participantsNon-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus Acetaminophen
Very bad11
Bad211
Moderate2122
Good2921
Very good42
SecondaryNumber of Participants With Overall Assessment on Study Drug by Investigator

Investigator was completed overall assessment on study drug by using a 5-point scale (-2 to 2; where, -2= very bad, 1= bad, 0=moderate, 1=good and 2=very good). Study drug refers specifically to the randomized treatment received from Day 29 to Day 85.

Time frame:
Day 85
Reported as:
Number · participants
Number of Participants With Overall Assessment on Study Drug by Investigator
participantsNon-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus Acetaminophen
Very bad10
Bad16
Moderate2125
Good3124
Very good32
SecondaryNumber of Participants With Categorical Swelling

Swelling was assessed by using a 4-point scale ranging from 0 to 3 where, 0=no swelling, 1=presence of cross fluctuation of fluid (PCFF), 2=patellar ballotment, and 3=swelling that distort the joint contours (SDJC).

Time frame:
Day 29, Day 57 and Day 85
Reported as:
Number · participants
Number of Participants With Categorical Swelling
participantsNon-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus Acetaminophen
Day 29; No swelling (n=56, 52)5245
Day 29; PCFF (n=56, 52)47
Day 57; No swelling (n=47, 41)4338
Day 57; PCFF (n=47, 41)43
Day 85; No swelling (n=55, 56)5346
Day 85; PCFF (n=55, 56)19
Day 85; Patellar ballotment (n=55, 56)11
SecondaryNumber of Participants With Categorical Tenderness

Tenderness was assessed by using a 4-point scale 0 to 3 where, 0= no tenderness, 1= complaint of tenderness, 2=complaint of tenderness with wincing (CTW), and 3=wincing and attempt to withdraw.

Time frame:
Day 29, Day 57 and Day 85
Reported as:
Number · participants
Number of Participants With Categorical Tenderness
participantsNon-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus Acetaminophen
Day 29; No tenderness(n=56, 52)3337
Day 29; Complaint of tenderness (n=56, 52)2214
Day 29; CTW (n=56, 52)01
Day 29; Wincing and attempt to withdraw (n=56, 52)10
Day 57; No tenderness(n=47, 41)3330
Day 57; Complaint of tenderness (n=47, 41)1410
Day 57; CTW (n=47, 41)01
Day 57; wincing and attempt to withdraw(n=47, 41)00
Day 85; No tenderness(n=55, 56)3944
Day 85; Complaint of tenderness (n=55, 56)1510
Day 85; CTW (n=55, 56)02
Day 85; Wincing and attempt to withdraw(n=55, 56)10

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-steroidal Anti-inflammatory Drugs (NSAIDs)—1/73 (1.4%)17/73 (23.3%)
Tramadol Hydrochloride Plus Acetaminophen—0/67 (0%)12/67 (17.9%)
Most frequent serious events
Most frequent serious events
EventNon-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus Acetaminophen
Thromboangiitis obliteransVascular disorders1/730/67
Most frequent other events
Most frequent other events
EventNon-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus Acetaminophen
NauseaGastrointestinal disorders7/734/67
ConstipationGastrointestinal disorders6/735/67
DizzinessGastrointestinal disorders6/735/67
DyspepsiaGastrointestinal disorders3/734/67

Baseline characteristics

Age Continuous
Age Continuous(years)Non-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus AcetaminophenTotal
Mean60.0 ± 8.062.3 ± 7.661.1 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Non-steroidal Anti-inflammatory Drugs (NSAIDs)Tramadol Hydrochloride Plus AcetaminophenTotal
Female6256118
Male111122
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2008
First posted
Mar 13, 2008
Start
May 2007
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Jun 24, 2013
Last update
Jul 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00635349
Responsible party
Sponsor
First posted
Mar 13, 2008
Start date
May 2007
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Jun 24, 2013
Last update
Jul 22, 2013

Study contacts

Janssen Korea, Ltd. Clinical Trial
study director · Janssen Korea, Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Acetaminophen

Start the discussion